Skip to main content

Charles Pitman

x
Charles Pitman

Charles is a member of the Healthcare team, specialising in European mid-cap and US large-cap pharmaceutical companies, as well as the COVID-19 pandemic. His recent work includes AbbVie: Guaranteed Immunity (Jan 2022, 218 pages) that analysed the $80bn global immunology industry, and a drug-level anlaysis of UCB in 12-Year Itch (Jan 2021, 132 pages). Since March 2020, Charles has helped the team to publish 92 times on the COVID-19 pandemic (over 2000 pages) with the most recent piece suggesting an end to threat of the virus in Western Europe, The End-emic is Near (Jan 2022, 15 pages). First joining Redburn in 2015, Charles has also worked in the aerospace and defence and financial modelling teams.

Contact Charles Pitman | Back to Analysts